Roquefort Therapeutics plc's latest marketcap:
As of 08/05/2025, Roquefort Therapeutics plc's market capitalization has reached $3.56 M. According to our data, Roquefort Therapeutics plc is the 45162th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.56 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -1,291,526.19 |
| Shares Out | 157.44 M |
| EPS (ttm) | -0.01 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/26/2025 |
Roquefort Therapeutics plc's yearly market capitalization.
| Date | Market Cap(£) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/05/2025 | £2.68 M | $3.56 M | -51.31% | 45162 |
| 12/31/2024 | £5.5 M | $6.88 M | -41.29% | 39655 |
| 12/29/2023 | £9.36 M | $11.92 M | 9.43% | 36324 |
| 12/30/2022 | £8.56 M | $10.35 M | 13.33% | 35805 |
| 12/31/2021 | £7.55 M | $10.21 M | 35481 |
Company Profile
About Roquefort Therapeutics plc
Roquefort Therapeutics plc is a leading biotechnology company focused on developing innovative medicines for cancer treatment. Established in 2020 and headquartered in London, UK, the company is dedicated to advancing novel therapies to address unmet medical needs in oncology.
Product Portfolio
The company's pipeline includes five patent-protected pre-clinical anti-cancer medicines:
- Midkine Antibodies: Demonstrated in vivo efficacy, toxicology studies, and orphan drug indication potential.
- Midkine RNA Oligonucleotide Therapeutics: Features novel anti-cancer gene editing capabilities.
- Midkine mRNA Therapeutics: Targets solid tumors with advanced therapeutic approaches.
- STAT-6 siRNA Therapeutics: Focuses on solid tumors with proven in vivo efficacy.
- MK Cell Therapy: Combines direct and natural killer cell-mediated anti-cancer action.
Frequently Asked Questions
-
What is Roquefort Therapeutics plc's (LON-ROQ) current market cap?As of 08/05/2025, Roquefort Therapeutics plc (including the parent company, if applicable) has an estimated market capitalization of $3.56 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Roquefort Therapeutics plc (LON-ROQ) rank globally by market cap?Roquefort Therapeutics plc global market capitalization ranking is approximately 45162 as of 08/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.